Literature DB >> 19126548

Growth factors outside of the platelet-derived growth factor (PDGF) family employ reactive oxygen species/Src family kinases to activate PDGF receptor alpha and thereby promote proliferation and survival of cells.

Hetian Lei1, Andrius Kazlauskas.   

Abstract

The vitreous contains a plethora of growth factors that are strongly implicated in the formation of fibroproliferative diseases such as proliferative vitreoretinopathy. Although platelet-derived growth factors (PDGFs) are present in the vitreous, vitreal growth factors outside of the PDGF family activated the PDGF alpha receptor (PDGFRalpha) and promoted disease progression in a rabbit model of proliferative vitreoretinopathy (H. Lei, G. Velez, P. Hovland, T. Hirose, D. Gilbertson, and A. Kazlauskas (2008) submitted for publication.) In this report we investigated the mechanism by which non-PDGFs activated PDGFRalpha. We found that non-PDGFs increased the cellular level of reactive oxygen species (ROS) and that this event was necessary and sufficient for phosphorylation of PDGFRalpha. We speculated that the underlying mechanism was ROS-mediated inhibition of phosphotyrosine phosphatases, which antagonize receptor auto-phosphorylation. However, this did not appear to be the case. Non-PDGFs promoted tyrosine phosphorylation of catalytically inactive PDGFRalpha, and thereby indicated that at least one additional tyrosine kinase was involved. Indeed, preventing expression or blocking the kinase activity of Src family kinases suppressed non-PDGF-dependent tyrosine phosphorylation of PDGFRalpha. Thus non-PDGFs increased the level of ROS, which activated Src family kinases and resulted in phosphorylation of PDGFRalpha. Finally, although non-PDGFs induced only modest phosphorylation of PDGFRalpha, proliferation and survival of cells in response to non-PDGFs was significantly enhanced by expression of PDGFRalpha. These studies reveal a novel mechanism for activation of PDGFRalpha that appears capable of enhancing the responsiveness of cells to growth factors outside of the PDGF family.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19126548      PMCID: PMC2649107          DOI: 10.1074/jbc.M808426200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  62 in total

1.  Gene transfer of soluble TGF-beta type II receptor inhibits experimental proliferative vitreoretinopathy.

Authors:  Y Oshima; T Sakamoto; T Hisatomi; C Tsutsumi; H Ueno; T Ishibashi
Journal:  Gene Ther       Date:  2002-09       Impact factor: 5.250

2.  PI3K and PLCgamma play a central role in experimental PVR.

Authors:  Yasushi Ikuno; Fee-Lai Leong; Andrius Kazlauskas
Journal:  Invest Ophthalmol Vis Sci       Date:  2002-02       Impact factor: 4.799

3.  EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF.

Authors:  N Prenzel; E Zwick; H Daub; M Leserer; R Abraham; C Wallasch; A Ullrich
Journal:  Nature       Date:  1999 Dec 23-30       Impact factor: 49.962

4.  Angiotensin II induces transactivation of two different populations of the platelet-derived growth factor beta receptor. Key role for the p66 adaptor protein Shc.

Authors:  S Heeneman; J Haendeler; Y Saito; M Ishida; B C Berk
Journal:  J Biol Chem       Date:  2000-05-26       Impact factor: 5.157

5.  Reversible oxidation and inactivation of protein tyrosine phosphatases in vivo.

Authors:  Tzu-Ching Meng; Toshiyuki Fukada; Nicholas K Tonks
Journal:  Mol Cell       Date:  2002-02       Impact factor: 17.970

6.  Attenuation of experimental proliferative vitreoretinopathy by inhibiting the platelet-derived growth factor receptor.

Authors:  Y Ikuno; F L Leong; A Kazlauskas
Journal:  Invest Ophthalmol Vis Sci       Date:  2000-09       Impact factor: 4.799

7.  Basic fibroblast growth factor, glutamine synthetase, and interleukin-6 in vitreous fluid from eyes with retinal detachment complicated by proliferative vitreoretinopathy.

Authors:  Ellen C La Heij; Marjo P H van de Waarenburg; Harriet G T Blaauwgeers; Alfons G H Kessels; Albert T A Liem; Charlotte Theunissen; Harry Steinbusch; Fred Hendrikse
Journal:  Am J Ophthalmol       Date:  2002-09       Impact factor: 5.258

8.  Novel growth factors involved in the pathogenesis of proliferative vitreoretinopathy.

Authors:  D R Hinton; S He; M L Jin; E Barron; S J Ryan
Journal:  Eye (Lond)       Date:  2002-07       Impact factor: 3.775

9.  The 5-HT transporter transactivates the PDGFbeta receptor in pulmonary artery smooth muscle cells.

Authors:  Yinglin Liu; Min Li; Rod R Warburton; Nicholas S Hill; Barry L Fanburg
Journal:  FASEB J       Date:  2007-05-15       Impact factor: 5.191

10.  HGF regulation of RPE proliferation in an IL-1beta/retinal hole-induced rabbit model of PVR.

Authors:  Gregory I Liou; Vytautas A Pakalnis; Suraporn Matragoon; Sara Samuel; M Ali Behzadian; Justin Baker; Ibrahim E Khalil; Penny Roon; Ruth B Caldwell; Richard C Hunt; Dennis M Marcus
Journal:  Mol Vis       Date:  2002-12-20       Impact factor: 2.367

View more
  50 in total

Review 1.  Emerging roles of PDGF-D signaling pathway in tumor development and progression.

Authors:  Zhiwei Wang; Aamir Ahmad; Yiwei Li; Dejuan Kong; Asfar S Azmi; Sanjeev Banerjee; Fazlul H Sarkar
Journal:  Biochim Biophys Acta       Date:  2010-04-28

2.  Serotonin transporter interacts with the PDGFβ receptor in PDGF-BB-induced signaling and mitogenesis in pulmonary artery smooth muscle cells.

Authors:  Wenying Ren; Stephanie W Watts; Barry L Fanburg
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2010-12-24       Impact factor: 5.464

3.  Growth factors outside the PDGF family drive experimental PVR.

Authors:  Hetian Lei; Gisela Velez; Peter Hovland; Tatsuo Hirose; Debra Gilbertson; Andrius Kazlauskas
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-03-25       Impact factor: 4.799

4.  Pathological signaling via platelet-derived growth factor receptor {alpha} involves chronic activation of Akt and suppression of p53.

Authors:  Hetian Lei; Gisela Velez; Andrius Kazlauskas
Journal:  Mol Cell Biol       Date:  2011-02-28       Impact factor: 4.272

5.  Vascular endothelial growth factor acts primarily via platelet-derived growth factor receptor α to promote proliferative vitreoretinopathy.

Authors:  Steven Pennock; Luis J Haddock; Shizuo Mukai; Andrius Kazlauskas
Journal:  Am J Pathol       Date:  2014-09-26       Impact factor: 4.307

6.  RasGAP Promotes Autophagy and Thereby Suppresses Platelet-Derived Growth Factor Receptor-Mediated Signaling Events, Cellular Responses, and Pathology.

Authors:  Hetian Lei; Cynthia X Qian; Jinghu Lei; Luis J Haddock; Shizuo Mukai; Andrius Kazlauskas
Journal:  Mol Cell Biol       Date:  2015-03-02       Impact factor: 4.272

7.  Ligand-Independent Activation of Platelet-Derived Growth Factor Receptor β during Human Immunodeficiency Virus-Transactivator of Transcription and Cocaine-Mediated Smooth Muscle Hyperplasia.

Authors:  Pranjali N Dalvi; Vijayalaxmi G Gupta; Brooke R Griffin; Amy O'Brien-Ladner; Navneet K Dhillon
Journal:  Am J Respir Cell Mol Biol       Date:  2015-09       Impact factor: 6.914

8.  Ranibizumab is a potential prophylaxis for proliferative vitreoretinopathy, a nonangiogenic blinding disease.

Authors:  Steven Pennock; David Kim; Shizuo Mukai; Matthew Kuhnle; Dal W Chun; Joanne Matsubara; Jing Cui; Patrick Ma; David Maberley; Arif Samad; Robert J Van Geest; Sarit L Oberstein; Reinier O Schlingemann; Andrius Kazlauskas
Journal:  Am J Pathol       Date:  2013-04-09       Impact factor: 4.307

9.  A novel function of p53: a gatekeeper of retinal detachment.

Authors:  Hetian Lei; Marc-Andre Rheaume; Jing Cui; Shizuo Mukai; David Maberley; Arif Samad; Joanne Matsubara; Andrius Kazlauskas
Journal:  Am J Pathol       Date:  2012-09       Impact factor: 4.307

10.  Hypoxia activates the K-ras proto-oncogene to stimulate angiogenesis and inhibit apoptosis in colon cancer cells.

Authors:  Min Zeng; Hirotoshi Kikuchi; Maria S Pino; Daniel C Chung
Journal:  PLoS One       Date:  2010-06-04       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.